12.99
-0.28(-2.11%)
Currency In USD
| Previous Close | 13.27 |
| Open | 13.17 |
| Day High | 13.39 |
| Day Low | 12.97 |
| 52-Week High | 15.74 |
| 52-Week Low | 2.69 |
| Volume | 5,425 |
| Average Volume | 46,308 |
| Market Cap | 34.81M |
| PE | -0.55 |
| EPS | -23.81 |
| Moving Average 50 Days | 11.91 |
| Moving Average 200 Days | 7.4 |
| Change | -0.28 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $54.4 as of January 22, 2026 at a share price of $12.99. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $79.6 as of January 22, 2026 at a share price of $12.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept (“POC”) data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
GlobeNewswire Inc.
Nov 12, 2025 1:00 PM GMT
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered into definitive agreements wit